Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05360784 · ClinicalTrials.gov registry record · Phase 3
"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 380
- Enrollment target
NCT05360784 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 380 participants.
The verdict
NCT05360784, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 380 participants
- Enrollment target
Study Summary
This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites. Participants with ocular redness will be randomized to receive either brimonidine tartrate ophthalmic solution 0.025%, preservative-free formulation, or Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will be treated with study drug for approximately 4 weeks.
Interventions
- DRUG Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
- DRUG Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2022-05-13 |
| Est. Completion | 2022-11-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05360784
The ClinicalTrials.gov registry entry for NCT05360784 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation is the first listed.
NCT05360784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05360784 about?
NCT05360784 is a clinical study titled ""Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"". This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites. Participants with ocular redness will be randomized to receive either brimonidine tartrate ophthalmic solution 0.025%, preser...
What is the current status of trial NCT05360784?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 380 participants. The study started on 2022-05-13. Estimated completion is 2022-11-23.
What interventions are being tested in trial NCT05360784?
The interventions under investigation include: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation (DRUG), Lumify® (brimonidine tartrate ophthalmic solution 0.025%) (DRUG).
Who is sponsoring clinical trial NCT05360784?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.